Angiogenic Growth Factors and Their Receptors in First-Trimester Human Decidua of Pregnancies Further Complicated By Preeclampsia or Fetal Growth Restriction
Restricted accessResearch articleFirst published online September, 2008
Angiogenic Growth Factors and Their Receptors in First-Trimester Human Decidua of Pregnancies Further Complicated By Preeclampsia or Fetal Growth Restriction
Disturbances in decidual and placental vascular development may play a role in the pathogenesis of pregnancy complications. This study focused on the role of angiogenic factors in the first trimester in the pathogenesis of preeclampsia (PE) and/or fetal growth restriction (FGR). First-trimester decidua was obtained during chorionic villous sampling.The expression of the angiogenic factors was determined by reverse transcriptase polymerase chain reaction and related to the pregnancy outcome. First-trimester decidua expressed all angiogenic factors.The differential expression of angiogenic factors appeared to be more prominent in FGR than in PE. These first-trimester samples provided a unique opportunity to obtain information regarding the onset of PE and FGR. First-trimester changes in angiogenic factor expression may well occur as a compensatory mechanism. This, in turn, may unintentionally set the stage for increased angiogenesis and altered decidual/placental vascular adaptation, which may be part of the pathogenesis of PE and/or FGR.
Ahmed A., Perkins J.Angiogenesis and intrauterine growth retardation. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000; 14:981-998.
2.
Ong S., Lash G., Baker PNAngiogenesis and placental growth in normal and compromised pregnancies . Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14:969-980.
3.
Torry DS, Hinrichs M., Torry RJDeterminants of placental vascularity. Am J Reprod Immunol . 2004;51:257-268.
4.
Luttun A., Carmeliet P.Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered ? J Clin Invest. 2003;111:600-602.
5.
Maynard SE, Min J., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sflt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
6.
Burton GJ, Jauniaux E., Watson ALMaternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd collection revisited . Am J Obstet Gynecol. 1999;181:718-724.
7.
Pijnenborg R. , Bland JM, Robertson WB, Brosens I.Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta. 1983;4:397-413.
8.
Zhou Y., McMaster M., Woo K., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160:1405-1423.
9.
Geva E., Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A., Jaffe RBHuman placental vascular development: vasculogenic and angiogenic transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1 and angiopoietin-2 . J Clin Endocrinol Metab. 2002;87:4213-4224.
10.
Das SK, Chakraborty I., Wang J., Dey SK, Hoffman LHExpression of vascular endothelial growth factor (VEGF) and VEGF-receptor messenger ribonucleic acids in the peri-implantation rabbit uterus. Biol Reprod. 1997;56: 1390-1399.
11.
Plaisier M. , Rodrigues S., Willems F., et al. Different degree of vascularisation and its relation to the expression of VEGF, PlGF, angiopoietins and their receptors in 1st trimester decidua. Fertil Steril . 2007;88:176-187.
12.
Chung J., Song Y., Wang Y., Magness RR, Zheng J.Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2004;89:2484-2490.
13.
Carmeliet P. , Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575-583.
14.
Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 . Nat Med. 2002;8:831-840.
15.
Sherer DM, Abulafia O.Angiogenesis during implantation, and placental and early embryonic development . Placenta. 2001;22:1-13.
16.
Geva E., Jaffe RBRole of angiopoietins in reproductive tract angiogenesis. Obstet Gynecol Surv. 2000;55:511-519.
17.
Maisonpierre PC, Suri C., Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
18.
Asahara T., Chen D., Takahashi T., et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83:233-240.
19.
Li XF, Charnock-Jones DS, Zhang E., Hiby S., Malik S., Day K.Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J Clin Endocrinol Metab. 2001 ; 86:1823-1834.
20.
Roberts JM, Cooper DWPathogenesis and genetics of preeclampsia. Lancet . 2001;357:53-56.
21.
Taylor RN, Grimwood J., Taylor RS, McMaster MT, Fisher SJ, North RALongitudinal serum concentrations of PlGF: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol . 2003;188:177-182.
22.
Kloosterman GJOver intra-uteriene groei en de intra-uteriene groeicurve. [Intrauterine growth and intrauterine growth curves]. Ned Tijdschr Verloskd Gynaecol.1969;69:349-365.
23.
Clark DE, Smith SK, He Y., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod. 1998;59:1540-1548.
24.
Tjoa ML, Levine RJ, Karumanchi SAAngiogenic factors in preeclampsia. Front Biosci. 2007;112:2395-2402.
25.
Ahmad S., Ahmed A.Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in pre-eclampsia. Circ Res. 2004 ;95:884-891.
26.
Hayman R., Brockelsby J., Kenny L., Baker P.Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. J Soc Gynecol Investig. 1999 ;6:3-10.
27.
Sugimoto H. , Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605-12608.
28.
Ranheim T., Staff AC, Henriksen T.VEGF mRNA is unaltered in decidual and placental tissues in preeclampsia at delivery. Acta Obstet Gynecol Scand. 2001;80:93-98.
29.
Sgambati E. , Marini M., Zappoli , et al. VEGF expression I the placenta from pregnancies complicated by hypertensive disorders. BJOG.2004;111:564-570.
30.
Lam C., Lim KH, Karumanchi SACirculating angiogenic factors in the pathogenesis and prediction of preeclampsia . Hypertension. 2005;46:1077-1085.
31.
Zhang EG, Smith SK, Baker PN, Charnock-Jones DSThe regulation and localization of angiopoietin-1, -2, and their receptor Tie2 in normal and pathologic human placentae. Mol Med. 2001;7:624-635.
32.
Levine RJ, Maynard SE, Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia . N Engl J Med. 2004; 350:672-683.
33.
Bosio PM, Wheeler T., Anthony F., Conroy R., O'Herlihy C., McKenna P.Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am J Obstet Gynecol.2001;184:146-152.
34.
Tsatsaris V. , Goffin F., Munaut C., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathological consequences.J Clin Endocrinol Metab . 2003 ;88:5555-5563.
35.
Burton GJOn `oxygen and placental villous development: origins of fetal hypoxia' . Placenta. 1997;18:625-626.
36.
Kingdom JCP , Kaufmann P.Oxygen and placental villous development: origins of fetal hypoxia. Placenta. 1997;18; 613-621.
37.
Regnault TRH , de Vrijer B., Galan HL, et al. The relationship between transplacental O2 diffusion and placental expression of PlGF, VEGF, and their receptors in a placental insufficiency model of fetal growth restriction . J Physiol. 2003;550: 641-656.
38.
Lyall F.Placental expression of VEGF in placentae of preeclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. Placenta. 1997;18: 269-276.
39.
Khaliq A., Dunk C., Jiang J., et al. Hypoxia downregulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab Invest. 1999;79:151-170.
40.
Erickson Hagen AS, Orbus RJ, Wilkening RB, Regnault TRH, Anthony RVPlacental expression of angiopoietin-1, angiopoietin-2 and Tie-2 during placental development in an ovine model of placental insufficiency-fetal growth restriction. Pediatr Res. 2005;58:1228-1232.
41.
Sharkey AM, Day K., McPherson A., et al.Vascular endothelial growth factor expression in humane endometrium is regulated by hypoxia. J Clin Endocrinol Metab. 2000;85: 402-409.
42.
Cooper JC, Sharkey AM, Charnock-Jones D., Palmer CR, Smith SKVEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia . BJOG. 1996;103:1191-1996.
